What Orchard Therapeutics does

Orchard Therapeutics is a commercial-stage biotechnology company headquartered in London with US operations in Boston, specializing in ex vivo autologous hematopoietic stem cell (HSC) gene therapies that use self-inactivating lentiviral vectors to deliver functional copies of defective genes into a patient's own blood stem cells. The corrected cells are reinfused and engraft in bone marrow, where they produce healthy blood cells, including microglial-like cells capable of crossing the blood-brain barrier to distribute therapeutic proteins throughout the central nervous system. The company's lead commercial product is Lenmeldy (US) / Libmeldy (EU), known generically as atidarsagene autotemcel, a one-time gene therapy approved for early-onset metachromatic leukodystrophy (MLD) and priced at $4.25-4.5 million per treatment.

Orchard was founded in 2015 by HSC gene therapy pioneers Bobby Gaspar and Adrian Thrasher, with roots in early gene therapy research conducted at Great Ormond Street Hospital from 1993 onward. The company went public on Nasdaq in October 2018 and was acquired by Kyowa Kirin Co., Ltd. in January 2024 for approximately $477 million, now operating as a UK subsidiary of the Japanese pharmaceutical firm. Revenue is generated through one-time per-treatment pricing on a single approved product, distributed via a network of qualified treatment centers with specialized expertise in hematopoietic stem cell transplantation. The pipeline includes OTL-203 for MPS-I (Hurler syndrome), OTL-201 for MPS-IIIA (Sanfilippo A), OTL-204 for frontotemporal dementia, and OTL-104 for the NOD2 form of Crohn's disease, alongside the acquired Strimvelis product for ADA-SCID. Customer segments include rare disease patients (primarily pediatric), healthcare professionals at specialized treatment centers, and patient advocacy organizations that the company partners with for disease awareness, newborn screening advocacy, and clinical trial enrollment.

Name

Orchard Therapeutics

Legal name

Orchard Therapeutics (Europe) Limited

Website

https://orchard-tx.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Orchard Therapeutics is a UK-based biotechnology company, now a Kyowa Kirin subsidiary, that develops ex vivo autologous HSC gene therapies using lentiviral vectors for severe inherited rare diseases. Its sole commercial product, Lenmeldy/Libmeldy for early-onset MLD, is priced at $4.25-4.5M per one-time curative treatment.

Ownership category

akta.pro rank

Product category

Gene Therapy Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)

akta.pro secondary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

Keywords

• Ex vivo gene therapy
• Lentiviral vector therapy
• Rare disease therapeutics
• Hematopoietic stem cell therapy
• Autologous cell therapy

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Libmeldy/Lenmeldy Product Sales: One-time ex vivo autologous gene therapy for metachromatic leukodystrophy (MLD) approved in Europe (Libmeldy) and US (Lenmeldy). Priced at $4.25-4.5 million per treatment as a potentially curative single-administration therapy.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Orchard Therapeutics develops and commercializes ex vivo autologous hematopoietic stem cell (HSC) gene therapies using lentiviral vectors to treat severe rare genetic diseases. Its approved products include Lenmeldy (US) and Libmeldy (EU/UK) for early-onset metachromatic leukodystrophy (MLD), and Strimvelis for ADA-SCID, sold as one-time potentially curative treatments priced at $4.25–4.5 million per patient and administered at certified treatment centers. The company also advances a pipeline of investigational HSC gene therapies for mucopolysaccharidosis (MPS-I, MPS-IIIA), frontotemporal dementia, and Crohn's disease.

Product overview

Orchard Therapeutics is a commercial-stage biopharmaceutical company developing HSC (hematopoietic stem cell) gene therapies for rare genetic diseases. The company's portfolio includes both approved and investigational therapies: Lenmeldy/Libmeldy (atidarsagene autotemcel) is the FDA-approved and EMA-approved treatment for metachromatic leukodystrophy (MLD); OTL-203 for mucopolysaccharidosis type I (MPS-I); OTL-201 for mucopolysaccharidosis type IIIA (MPS-IIIA); OTL-204 for frontotemporal dementia; and OTL-104 for Crohn's disease. The company also acquired Strimvelis from GSK, an EMA-approved therapy for ADA-SCID. All therapies use a lentiviral vector-based ex vivo autologous gene therapy approach where a patient's own blood stem cells are genetically modified to correct the underlying cause of disease in a single treatment.

Differentiator

Problem solved

Functional benefit

Products and services

• Lenmeldy / Libmeldy (atidarsagene autotemcel, OTL-200) One-time ex vivo autologous HSC gene therapy for early-onset metachromatic leukodystrophy (MLD), approved in the US as Lenmeldy and in the EU/UK/Switzerland as Libmeldy. Priced at $4.25-4.5 million per treatment in the US. Indicated for children with pre-symptomatic late infantile, pre-symptomatic early juvenile, or early-symptomatic early juvenile MLD.
• Strimvelis (autologous CD34+ cells transduced to express ADA) First ex vivo autologous gene therapy approved by the European Medicines Agency (EMA) for adenosine deaminase severe combined immunodeficiency (ADA-SCID). Acquired by Orchard from GSK in 2018. Not approved outside the European Union.
• OTL-203 Investigational ex vivo autologous HSC gene therapy for mucopolysaccharidosis type I (MPS-I), specifically for patients with Hurler syndrome. Has received rare pediatric disease designation from the FDA.
• OTL-201

Quantifiable outcome

• 160+ patients treated with ex vivo autologous gene therapies across 6+ disease areas with up to 10 years follow-up
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered minor, core and major.

• Oxford Nanopore TechnologiesminorStrategic or Co-development Partner · 1 March 2026Both Orchard (as Kyowa Kirin subsidiary) and Oxford Nanopore announced separate UK-Japan life sciences collaborations during UK Prime Minister's visit to Japan, with Orchard committing £11 million to UK gene therapy R&D.
• Kyowa KirincoreStrategic or Co-development Partner · 1 January 2024Orchard Therapeutics was acquired by Kyowa Kirin, a Japan-based pharmaceutical company, in January 2024 for $477 million. The acquisition strengthened Kyowa Kirin's portfolio in rare and complex diseases through Orchard gene therapy platforms. Orchard operates as a UK subsidiary of Kyowa Kirin.
• San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget)coreStrategic or Co-development PartnerSR-Tiget in Milan, Italy is the origin of multiple Orchard programs including Libmeldy/Lenmeldy (OTL-200), OTL-203 (MPS-I), and other gene therapies. The partnership involves ongoing clinical development collaboration with research conducted at San Raffaele Hospital.
• GlaxoSmithKline (GSK)coreStrategic or Co-development PartnerOrchard acquired GSK's portfolio of gene therapies for rare inherited diseases in April 2018, including Strimvelis and clinical-stage programs for MLD, WAS, and beta thalassemia. The original collaboration began in October 2010 between GSK and SR-Tiget.
• Great Ormond Street HospitalmajorStrategic or Co-development PartnerClinical trial collaboration partner for ADA-SCID and X-CGD gene therapy studies. Orchard founders Bobby Gaspar and Adrian Thrasher conducted first patient trials at Great Ormond Street Hospital in London starting in 2012.
• GénéthonmajorStrategic or Co-development PartnerStrategic alliance announced December 2017 to develop ex vivo autologous gene therapy for X-linked chronic granulomatous disease (X-CGD).
• The University of ManchestermajorTechnology or IntegrationLicensed a preclinical program in mucopolysaccharidosis type IIIB (MPS-IIIB) from The University of Manchester, UK in November 2017.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• bluebird bio: Closest direct peer — develops ex vivo lentiviral gene therapies for rare genetic diseases (sickle cell, beta-thalassemia, cerebral adrenoleukodystrophy) using autologous hematopoietic stem cells, the same core platform architecture Orchard uses.
• Rocket Pharmaceuticals: Clinical-stage gene therapy company developing lentiviral and AAV therapies for rare pediatric diseases including Fanconi anemia, LAD-I, and Danon disease, with comparable ex vivo HSC gene correction approach and rare disease focus.
• AVROBIO: Ex vivo lentiviral HSC gene therapy company developing one-time treatments for lysosomal storage diseases including cystinosis, Fabry disease, and Gaucher disease — directly comparable platform and indication overlap with Orchard's MPS programs.
• uniQure: Gene therapy company developing AAV-based treatments for rare diseases including hemophilia B (Hemgenix) and Huntington's disease, sharing Orchard's focus on one-time curative therapies for severe genetic conditions.
• Sarepta Therapeutics: Gene therapy company with FDA-approved AAV therapies for Duchenne muscular dystrophy (Elevidys), sharing the neuromuscular/rare disease space and the challenge of pricing/customer concentration in ultra-rare populations.

Broad incumbents

• BioMarin Pharmaceutical: Established rare disease biopharma with commercial gene therapy Roctavian for hemophilia A and a broader enzyme replacement portfolio — overlaps with Orchard in pricing/distribution of ultra-rare disease therapies but uses AAV rather than lentiviral HSC.
• Novartis Gene Therapies: Major pharmaceutical company with approved gene therapies Kymriah (CAR-T) and Zolgensma (AAV for SMA), competing in the same one-time curative treatment paradigm for severe genetic diseases.
• Spark Therapeutics (Roche): Acquired by Roche in 2019; pioneered FDA-approved gene therapy Luxturna for inherited retinal disease, providing a comparable model of AAV gene therapy commercialization in ultra-rare genetic conditions.
• Pfizer (Gene Therapy Division): Major pharmaceutical with rare disease gene therapy investments including Beqvez (AAV for hemophilia B) and sickle cell programs, sharing the rare disease curative therapy market dynamics but operating at vastly greater scale.

Emerging players

• CRISPR Therapeutics: Gene-editing platform company developing ex vivo CRISPR-based therapies (Casgevy for sickle cell disease) using autologous hematopoietic stem cells — directly comparable delivery modality and target cell type, but with a different gene-modification mechanism.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/orchard_tx
• LinkedInlinkedin.com/company/orchard-therapeutics

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds6 records

Investors32 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orchard Therapeutics